Hypothyroidism itself has not been shown to directly cause cancer in most organs, and for some cancer types, the evidence actually points in the opposite direction. But the picture is far from simple. Elevated TSH, the hallmark hormone of an underactive thyroid, is linked to a higher likelihood of thyroid cancer specifically, and the autoimmune inflammation that often underlies hypothyroidism carries its own distinct risks. The confusion stems partly from the fact that “hypothyroidism” is not one condition with one mechanism; it involves hormonal shifts, immune dysfunction, and metabolic changes that each relate to cancer in different and sometimes contradictory ways.
TSH Levels and Thyroid Cancer Risk
The strongest association between hypothyroidism and cancer involves the thyroid gland itself, and the key player is TSH. In hypothyroidism, the pituitary gland pumps out more TSH to try to coax the underperforming thyroid into producing hormones. That extra TSH stimulates thyroid tissue, and multiple studies have found that higher TSH levels track with a greater chance that a thyroid nodule turns out to be cancerous. One study of patients with thyroid nodules found that the likelihood of malignancy was about 16% when TSH was very low compared to roughly 52% when TSH was elevated above 5.0 mIU/liter. Even within the normal TSH range, having a level above the population average was associated with a significantly greater chance of cancer than having a level below the average. Higher TSH was also linked to more advanced disease at diagnosis.1The Journal of Clinical Endocrinology & Metabolism. Higher Serum Thyroid Stimulating Hormone Level in Thyroid Nodule Patients Is Associated with Greater Risks of Differentiated Thyroid Cancer and Advanced Tumor Stage
Other research has confirmed this pattern independently. In patients with diagnosed thyroid cancer, the mean TSH was significantly higher than in patients with benign nodules, regardless of age. Higher TSH was also independently associated with extrathyroidal extension, a sign that the cancer has grown beyond the thyroid capsule.2PubMed Central. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension A separate analysis similarly found that each unit increase in TSH raised the likelihood of malignancy in thyroid nodules by about one and a half times.3PubMed Central. Thyroid TSH level as a risk factor of thyroid malignancy for nodules in euthyroid patients
Does this mean hypothyroidism causes thyroid cancer? Not quite. TSH acts as a growth signal for thyroid cells, so it makes sense that more TSH could push nodules toward malignancy or help existing cancers grow more aggressively. But TSH is also found on the surface of other tissues, including ovarian and liver cells, where it can influence cell behavior through similar growth-promoting pathways.4PubMed Central. The Molecular Function and Clinical Role of Thyroid Stimulating Hormone Receptor in Cancer Cells The relationship between TSH and thyroid nodules may also partly reflect detection bias: people with thyroid problems get more ultrasounds, so more nodules get found and biopsied in the first place.
When Hashimoto’s Is the Underlying Cause
Most hypothyroidism in developed countries is caused by Hashimoto’s thyroiditis, an autoimmune condition where the immune system attacks the thyroid. And Hashimoto’s has its own cancer story, separate from the TSH question. A systematic review and meta-analysis found that Hashimoto’s was significantly associated with thyroid malignancies overall, with particularly strong links to papillary thyroid cancer, medullary thyroid cancer, and thyroid lymphoma. The association with lymphoma was especially striking, with roughly a 13-fold increased odds compared to people without Hashimoto’s.5PubMed Central. Is Hashimoto thyroiditis associated with increasing risk of thyroid malignancies? A systematic review and meta-analysis
Primary thyroid lymphoma is rare in the general population, but among patients who develop it, essentially all of them have a history of Hashimoto’s thyroiditis, which has been estimated to increase the risk of this particular cancer by 40 to 80 times.6PubMed Central. The Risk of Developing Lymphoma among Autoimmune Thyroid Disorder Patients The chronic inflammation and immune cell infiltration of the thyroid in Hashimoto’s creates an environment where lymphoid tissue can accumulate and, in rare cases, transform into lymphoma. The oxidative stress and inflammatory environment that accompany Hashimoto’s are believed to participate in carcinogenesis more broadly.7PubMed. Role of papillary thyroid carcinoma patients with Hashimoto thyroiditis: evaluation of oxidative stress and inflammatory markers
The practical takeaway here is that hypothyroidism caused by Hashimoto’s carries a different risk profile than hypothyroidism caused by, say, iodine deficiency or surgical removal of part of the thyroid. If you have Hashimoto’s, the risk is not so much from the low thyroid hormone levels themselves as from the ongoing autoimmune inflammation in your thyroid. Regular thyroid monitoring and ultrasound follow-up when nodules are present become more relevant in that context.
What About Cancers Outside the Thyroid
When researchers have looked at whether hypothyroidism raises the risk of cancer in general, the findings have been reassuringly mixed. A systematic review examining subclinical hypothyroidism and overall cancer risk found that a large Norwegian population study showed no meaningful association: the adjusted hazard ratio for all cancers among people with elevated TSH was 0.96, which is essentially no difference. The study also found no increased risk for the most common individual cancer types including lung, colon, prostate, and breast cancer.8PubMed Central. Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review
On the other hand, a large Taiwanese cohort study found that people with subclinical hypothyroidism had about a 50% higher risk of dying from cancer compared to those with normal thyroid function, after adjusting for age, smoking, obesity, and other factors.9PLOS ONE. Subclinical Hypothyroidism Is Associated with Increased Risk for Cancer Mortality in Adult Taiwanese—A 10 Years Population-Based Cohort These two studies measured slightly different things, cancer incidence versus cancer mortality, and were conducted in very different populations. It is possible that hypothyroidism does not increase how often cancer appears but does affect how well people survive it, perhaps through delayed diagnosis, differences in treatment response, or the metabolic burden of untreated thyroid disease layered on top of cancer treatment.
For specific organs, the evidence is scattered and sometimes paradoxical. A study within the Women’s Health Initiative found no significant differences in breast cancer rates, stages, or tumor characteristics between postmenopausal women with thyroid disorders and those without.10PubMed Central. Breast Cancer Risk in Postmenopausal Women with Medical History of Thyroid Disorder in the Women’s Health Initiative A Taiwanese population study actually found that hypothyroidism was associated with a lower risk of colorectal cancer, with about a 22% reduction in colon cancer and a 45% reduction in rectal cancer.11PubMed Central. Association Between Thyroid Disorders and Colorectal Cancer Risk in Adult Patients in Taiwan A large Spanish population study similarly found decreased risk of colorectal, gastric, pancreatic, bladder, and prostate cancers in people with hypothyroidism.12PLoS ONE. Malignant neoplasms in people with hypothyroidism in Spain
One notable exception is liver cancer. A case-control study of patients with liver cancer who had no known liver disease found that hypothyroidism was significantly more common among the cancer cases than among controls, with the association persisting after adjusting for metabolic syndrome factors. The effect estimates were large, though the confidence intervals were wide because relatively few patients in the study had hypothyroidism.13Clinical Gastroenterology and Hepatology. Hypothyroidism: A Possible Risk Factor for Liver Cancer in Patients With No Known Underlying Cause of Liver Disease This finding needs more research before drawing firm conclusions, but it is intriguing because the liver is heavily involved in thyroid hormone metabolism and the TSH receptor is expressed in liver tissue.
Why Low Thyroid Hormones Might Actually Slow Some Cancers
The finding that hypothyroidism is linked to lower rates of certain cancers is not as strange as it first sounds. Thyroid hormones are metabolic accelerators. They promote cell growth, increase blood supply to tissues, and ramp up metabolic activity. These are all things that established tumors need to thrive. When thyroid hormone levels are low, the body’s overall metabolic pace slows, and at the cellular level, certain growth-promoting pathways receive less stimulation.
Research has shown that thyroid hormones, particularly T4, can bind to a receptor on the cell surface called integrin αvβ3, activating a signaling pathway that promotes cancer cell growth.14PubMed Central. Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers Less circulating T4 means less fuel for that pathway. In prostate cancer, the picture is similar: higher thyroid hormone levels, not lower ones, have been associated with increased cancer incidence, and a protein that sequesters T3 inside cells (blocking it from reaching its receptors) appears to act as a brake on aggressive tumor growth.15Int J Cancer. Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer The crosstalk between thyroid hormones and androgen signaling adds another layer: because androgen pathways drive prostate cancer, and thyroid hormones can amplify androgen activity, hyperthyroidism may be the greater concern for prostate cancer rather than hypothyroidism.16PubMed Central. The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications
This does not mean hypothyroidism is protective in any clinically useful sense. You would not leave thyroid disease untreated hoping for a cancer benefit; the metabolic damage from uncontrolled hypothyroidism causes far more harm than any theoretical reduction in cancer risk. But it helps explain why the blanket fear that hypothyroidism “causes cancer” is an oversimplification.
The Role of Obesity and Metabolic Confounders
One of the hardest puzzles in studying the link between thyroid disorders and cancer is teasing apart what the thyroid dysfunction itself is doing versus what the metabolic problems that travel with it are doing. Hypothyroidism often leads to weight gain, elevated cholesterol, and insulin resistance. All of these are independent risk factors for several cancer types. When studies find a higher cancer rate in people with hypothyroidism, the thyroid condition may be a bystander rather than a driver.
A large prospective U.S. cohort study found that obesity-related metabolic conditions, including metabolic syndrome, dyslipidemia, and polycystic ovary syndrome (PCOS), were each independently associated with thyroid cancer risk. Even after adjusting for body mass index, dyslipidemia still carried about a 35% increased risk and PCOS nearly doubled the risk.17PubMed Central. Obesity, obesity-related metabolic conditions, and risk of thyroid cancer in women: results from a prospective cohort study (Sister Study) Since hypothyroidism often produces exactly these metabolic conditions, any study that does not carefully separate the thyroid dysfunction from its metabolic consequences may attribute risk to hypothyroidism that really belongs to the metabolic environment.
Well-designed studies try to adjust for these confounders, but no observational study can perfectly eliminate them. This is one reason the evidence on hypothyroidism and cancer remains so inconsistent across populations and study designs. It also means that managing the metabolic complications of hypothyroidism, keeping weight, cholesterol, and blood sugar in check, may matter as much as the thyroid replacement therapy itself when it comes to long-term cancer risk.
Treatment-Related Risks Worth Knowing About
For people already diagnosed with thyroid cancer, the treatments themselves can influence the risk of developing a second, unrelated cancer down the road. Two treatment factors have drawn attention: levothyroxine suppression therapy and radioactive iodine.
After thyroid cancer surgery, many patients are placed on levothyroxine at doses high enough to suppress TSH, the idea being to remove the growth signal that could fuel any remaining cancer cells. But a large Korean cohort study found that higher levothyroxine doses were associated with a greater risk of subsequent primary cancers. Patients in the highest dose group had roughly a 27% increased risk of developing a new cancer compared to those not taking levothyroxine, with stomach, colorectal, liver, and pancreatic cancers showing the strongest associations.18Endocrinology and Metabolism. Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine The concern is that suppressive doses effectively create a mild hyperthyroid state, and as discussed earlier, higher thyroid hormone levels can stimulate growth pathways in various tissues.
Radioactive iodine treatment presents a different kind of risk. A nationwide study found no significant increase in second primary malignancies for patients who received cumulative doses of 100 mCi or less. But higher cumulative doses showed progressively increasing risk: about a 21% increase at 101 to 200 mCi, roughly a 42% increase at 201 to 300 mCi, and close to a 69% increase above 300 mCi.19PubMed Central. Second Primary Malignancy After Radioiodine Therapy in Thyroid Cancer Patient: A Nationwide Study These findings influence how aggressively clinicians use radioactive iodine, particularly for low-risk thyroid cancers where the treatment may cause more harm than it prevents.
The Immunotherapy Twist
One of the more counterintuitive findings in recent cancer research involves immunotherapy drugs called immune checkpoint inhibitors. These drugs work by unleashing the immune system to attack tumors, but they frequently cause thyroid inflammation as a side effect, often resulting in hypothyroidism. And patients who develop that thyroid side effect tend to do better.
In a cohort of patients with non-small cell lung cancer receiving checkpoint inhibitors, those who developed thyroid dysfunction had a median overall survival of nearly 30 months compared to about 8 months for those who did not. Their progression-free survival was also dramatically longer.20PubMed Central. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer A meta-analysis across lung cancer patients confirmed that both hypothyroidism and hyperthyroidism triggered by these drugs were associated with improved survival.21PubMed Central. Immune checkpoint inhibitors-induced thyroid dysfunction improves the prognosis of patients with lung cancer: a meta-analysis and systematic review Studies in broader groups of patients with advanced solid tumors found similar patterns: those who developed hypothyroidism during treatment had better tumor response rates and longer progression-free survival.22PubMed Central. Correlation between thyroid dysfunction and efficacy of immune checkpoint inhibitors in patients with advanced solid tumors
The likely explanation is not that hypothyroidism itself fights cancer. Rather, the thyroid damage is a marker of a more vigorous immune response. A patient whose immune system is activated enough by the drug to attack their thyroid probably also has a more aggressive immune attack going on against their tumor. The thyroid is collateral damage from an otherwise beneficial immune activation. This is a useful reminder that the relationship between thyroid problems and cancer is rarely one of simple cause and effect: sometimes the association runs in reverse, sometimes it reflects a shared underlying process, and sometimes the thyroid is just caught in the crossfire.
Epigenetic Changes in Thyroid Tissue
Research into how thyroid cancers develop at the molecular level has pointed to epigenetic changes, modifications that alter how genes are read without changing the DNA sequence itself. Abnormal patterns of DNA methylation and shifts in small RNA molecules called microRNAs have been identified in thyroid cancers, and these changes can silence tumor-suppressor genes or activate growth-promoting ones.23PubMed Central. Epigenetic modifications in human thyroid cancer Chronic inflammation, as seen in Hashimoto’s thyroiditis, is one of the environmental pressures that can drive epigenetic changes over time. This gives a plausible molecular bridge between the autoimmune inflammation of Hashimoto’s and the eventual development of thyroid cancer in a small subset of patients, though the vast majority of people with Hashimoto’s will never develop thyroid malignancy. The field is still working out which specific epigenetic alterations are most clinically meaningful and whether monitoring them could one day help identify who among the millions of people with autoimmune thyroid disease warrants closer cancer surveillance.